BioAlliance Pharma Announces Grant of of Organ Designation for clonidine Lauriad™ in Europe

PARIS--(BUSINESS WIRE)--Regulatory News:

BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced that clonidine Lauriad™ has been granted orphan designation by the European Commission in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer.

MORE ON THIS TOPIC